Baxter proporciona terapias esenciales para enfermedades renales, cuidado hospitalario y procedimientos quirúrgicos, con más de 85 años de innovación en cuidado de la salud sirviendo a poblaciones de pacientes envejecidas.
Data updated Feb 15 · Source: Twelve Data
Baxter International, a major medical products and renal care company, presents a complex investment case. The stock has suffered a dramatic decline"down 74% over five years and 35% over the past year"reflecting significant operational challenges, debt concerns from the Hill-Rom acquisition, and the recent divestiture of its kidney care segment (Vantive). The remarkably low P/E of 4.95 with EPS of $4.00 suggests either deep value or earnings that may not be sustainable in their current form post-restructuring.
Bull case: Baxter's core hospital products and medication delivery businesses serve essential healthcare needs. The aging population thesis remains intact as elderly patients disproportionately consume hospital supplies, IV solutions, and infusion therapies. At under $20, much bad news appears priced in, and recent 30/60-day momentum suggests stabilization.
Bear case: Heavy debt load, ongoing restructuring risk, and the separation from its kidney care business removes a key aging-population growth driver. The 5-year destruction of shareholder value raises governance concerns. Trading near 52-week lows with the 180-day decline of 35% signals persistent institutional selling.
Baxter offers turnaround potential but carries substantial execution risk.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Cada trader tiene una estrategia que se ve genial en su cabeza. El backtesting es cómo descubres si realmente funciona. Aquí hay cómo probar estrategias correctamente, qué métricas importan y por qué la mayoría de los resultados de backtest son demasiado buenos para ser verdad.
Powered by Rexiew